Synapse - Karen Autio

Results (120)

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

Meeting Abstract

Garon, E. B.; Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, W. M.; Patel, M. R.; Autio, K. A.; Papadopoulos, K. P.; Naing, A.; Gabrail, N.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Meeting Abstract

Plummer, R.; Sanborn, R. E.; de Vries, E. G. E.; Lorusso, P.; Arkenau, H. T.; Uboha, N.; Wydmanski, J.; Fidler, M. J.; Boni, V.; Garcia-Corbacho, J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Meeting Abstract

Naing, A.; Autio, K. A.; Falchook, G. S.; Meric-Bernstam, F.; Litton, J. K.; Ibrahim, N. K.; Hung, A.; Oft, M.; Leveque, J.; Patel, M. R.
Annals of Oncology (2018)

Fulltext@MSK | Save

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Meeting Abstract

Hecht, J. R.; Naing, A.; Falchook, G. S.; Patel, M. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Javle, M.; Bendell, J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

Meeting Abstract

Boni, V.; Garcia-Corbacho, J.; Ott, P. A.; Cho, D. C.; Autio, K. A.; Uboha, N.; Spira, A. I.; Humphrey, R.; Will, M.; Naing, A.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Meeting Abstract

Autio, K. A.; Naing, A.; Hung, A.; Oft, M.; Leveque, J.; Falchook, G. S.
Annals of Oncology (2018)

Fulltext@MSK | Save

Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial

Meeting Abstract

Lyman, S. K.; Gordon, J.; DuPage, A.; Pramanik, P.; Howng, B.; Winter, M. B.; Popova, I. K.; Vasiljeva, O.; Jones, J.; Wong, K.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1

Meeting Abstract

Garon, E.; Wong, D.; Schneider, J.; Aliumaily, R.; Korn, W.; Infante, J.; Patel, M.; Autio, K.; Papadopoulos, K.; Naing, A.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression